GlobalData
GlobalData

Francesca.Hutton@globaldata.com

  • Home
  • Author: Francesca.Hutton@globaldata.com

Copiktra Wins FDA Approval in FL, CLL, and SLL, but its commercial prospects are limited, says GlobalData

Following Verastem’s Copiktra (duvelisib) accelerated approval for the treatment of third-line follicular lymphoma (FL) in September 2018, as well as its standard approval for third-line chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): Arshad Ahad, Oncology and Hematology Analyst GlobalData, offers his view on its commercial prospects: “Copiktra may have trouble gaining commercial traction […]
Read more

Knowledge about current contraceptive options is still a problem in highly developed countries, says GlobalData

Women in the US are still not fully aware about the available choices of contraceptives and receive outdated or incorrect counselling as their general providers are not familiar with currently available options, particularly the long-acting reversible methods, according to GlobalData, a leading data and analytics company. September 26 marks World Contraception Day (WCD), which aims […]
Read more

Imfinzi EU approval will add to the escalating competition of PD-(L)1 inhibitors, says GlobalData

Following AstraZeneca’s announcement on 25 September 2018 that the European Commission approved its PD-L1 inhibitor, Imfinzi (durvalumab) as monotherapy for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy, Edit Kovalcsik, […]
Read more

New tools from IBM and Google reveal just how hard it is to build trust in Artificial Intelligence, says GlobalData

The unseen dangers inherent in Artificial Intelligence (AI) are proving the importance of IBM and Google’s diverse approach to this multifaceted problem, Brad Shimmin, Service Director at GlobalData, a leading data and analytics company, offers his perspective on this important issue, “Artificial Intelligence (AI) has already changed the way consumers interact with technology and the […]
Read more

Limited access to novel therapies could hinder effective personalized cancer treatment in the UK, says GlobalData

NICE recently rejected NHS funding of Kymriah for DLBCL despite recognizing that the drug has significant clinical benefits. As a result, patients with DLBCL in the UK could now potentially lose out on receiving life-saving treatment, according to GlobalData, a leading data and analytics company. Following the EMA approval of Novartis’ Kymriah (tisagenlecleucel) for refractory/relapsed […]
Read more

Coca-Cola’s acquisition of Costa Coffee is set to take over supermarket shelves, says GlobalData

Coca-Cola’s acquisition of Costa Coffee offers the opportunity to turbo-charge the brand’s retail operations, and become a mainstay of supermarket shelves worldwide, says GlobalData, a leading data and analytics company. Ronan Stafford, Lead Consumer Analyst at GlobalData, comments, “With Costa Coffee operating in many of the world’s largest retail markets for hot coffee, Coca-Cola will […]
Read more

NHS victory over Bayer and Novartis could have significant impact on UK ophthalmology sales, says GlobalData

Following a High Court case won by twelve NHS Clinical Commissioning Groups (CCGs) in favor of prescribing the significantly cheaper anti-vascular endothelial growth factor (anti-VEGF), Avastin (bevacizumab), over Novartis’ and Bayer’s licensed anti-VEGF eye drugs, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the likely outcome […]
Read more

With Alzheimer’s treatment stalled, promising pipeline drugs and a shift in perception could be key to tackling the disease, says GlobalData

As World Alzheimer’s Day approaches (21 September) with the aim of raising global awareness and understanding of the issues faced by people affected by dementia it’s timely to reflect that no new drug for Alzheimer’s disease (AD) has been approved in the past 16 years, despite more than 400 clinical trials and billions of dollars […]
Read more

Number of respiratory conditions will continue to rise if UK air pollution goes unchecked, says GlobalData

The number of people suffering from respiratory indications and the severity of those already suffering from the various diseases is expected to increase if air pollution in the UK goes unchecked, says GlobalData, a leading data and analytics company. According to GlobalData’s reports: ‘PharmaPoint: Asthma’ states that the prevalence of asthma in the UK hovers […]
Read more

Regeneron’s supplemental biologics license application of Eylea for the treatment of diabetic retinopathy could slow its downfall, says GlobalData

Following Regeneron’s announcement that the FDA has accepted to review a supplemental biologics license application (sBLA) of Eylea for the treatment of diabetic retinopathy, Edit Kovalcsik, Managing Analyst at GlobalData, a leading data and analytics company, offers her view on the impact of this indication expansion on the Eylea market; “Regeneron’s Eylea (aflibercept), a vascular […]
Read more
1 13 14 15 16